Novartis Shows Commitment to CAR T Cell Strategy
Novartis Shows Commitment to CAR T Cell Strategy image
Novartis Shows Commitment to CAR T Cell Strategy
Posted Apr 20, 2017

In August of last year, it was reported that Novaris was integrating its separate gene and cell therapy unit back into the company. Some thought it showed a retraction of a commitment to the division's CAR T Cell work, but the Swiss company says it is aggressively pursuing steps forward. Vas Narasimhan, MD and global head of drug development and CMO at Novartis said that the inclusion back into the main corporate structure was due to its significant potential. According to a recent article in Fierce Biotech, "its leading CAR-T candidate, CTL019 (tisagenlecleucel), now has two FDA breakthrough tags in two blood cancers, and was given a priority review for the med by the agency at the end of March."

We had incubated the technology which came out of [its 2012 CAR-T deal] with Penn as a dedicated unit, and that was something that made sense: If you had immediately put that into the larger infrastructure of Novartis, it would have got lost, especially in the early stages when it was risky and it was unclear if this would be tractable," he said.
 Novartis and Kite Pharma are now in a heated first-to-market race for this exciting therapy. Narasimhan says that the first two diseases of focus will be acute lymphoblasic leukemia (ALL) in pediatric and young adult patients and diffuse large B-cell lymphoma as well as a combined study in Europe.
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811